Business Description
Annexon Inc
NAICS : 541714
SIC : 2834
Description
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | -0.23 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -27.2 | |||||
| 3-Year EPS without NRI Growth Rate | -28.2 | |||||
| 3-Year FCF Growth Rate | -23.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 81.68 | |||||
| 9-Day RSI | 76.39 | |||||
| 14-Day RSI | 71.4 | |||||
| 6-1 Month Momentum % | -3.08 | |||||
| 12-1 Month Momentum % | -28.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.59 | |||||
| Quick Ratio | 13.59 | |||||
| Cash Ratio | 13.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -49.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -64.38 | |||||
| ROA % | -52.47 | |||||
| ROIC % | -346.48 | |||||
| ROC (Joel Greenblatt) % | -399.94 | |||||
| ROCE % | -56.73 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.36 | |||||
| Price-to-Tangible-Book | 1.36 | |||||
| EV-to-EBIT | -0.77 | |||||
| EV-to-EBITDA | -0.79 | |||||
| EV-to-FCF | -0.9 | |||||
| Price-to-Net-Current-Asset-Value | 1.59 | |||||
| Price-to-Net-Cash | 1.64 | |||||
| Earnings Yield (Greenblatt) % | -129.87 |
